Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

Cathie Wood's ARK Invest exchange-traded funds adjusted several holdings on March 3, adding to select technology and aviation names while trimming others.Among

BioNTech (NASDAQ: BNTX - Get Free Report) will likely be posting its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.57) per share and revenue of $941.9940 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q4 2025 earning overview page

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. At a $27.6B market cap and ~$11B enterprise value, BNTX's pipeline—including Pumitamig, ADCs, and mRNA vaccines—is valued conservatively by the market. Scenario analysis shows downside is cushioned by cash, while upside hinges on pivotal oncology data over the next 12–18 months.

MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, March 10, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m.

Biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNexspike infringes a patent related to BioNTech and Pfizer's competing shot Comirnaty.

Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective.

Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the medium term.

BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BioNTech (NASDAQ: BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to highlight its transition back toward oncology, outline a slate of upcoming clinical readouts, and discuss how it plans to deploy its cash resources while continuing to fund late-stage development. Company update: shifting focus back to oncology Chief Executive Officer Ugur